Enfusion (NYSE:ENFN – Get Free Report) and VTEX (NYSE:VTEX – Get Free Report) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Volatility and Risk
Enfusion has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, VTEX has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Valuation and Earnings
This table compares Enfusion and VTEX”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Enfusion | $201.61 million | 7.00 | $6.03 million | $0.03 | 364.53 |
VTEX | $226.71 million | 3.94 | -$13.69 million | $0.07 | 69.79 |
Profitability
This table compares Enfusion and VTEX’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Enfusion | 1.70% | 6.67% | 4.86% |
VTEX | 3.97% | 3.60% | 2.53% |
Analyst Ratings
This is a summary of current ratings and target prices for Enfusion and VTEX, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Enfusion | 0 | 2 | 2 | 0 | 2.50 |
VTEX | 0 | 1 | 2 | 0 | 2.67 |
Enfusion presently has a consensus price target of $11.83, indicating a potential upside of 8.21%. VTEX has a consensus price target of $8.07, indicating a potential upside of 65.13%. Given VTEX’s stronger consensus rating and higher probable upside, analysts clearly believe VTEX is more favorable than Enfusion.
Insider and Institutional Ownership
81.1% of Enfusion shares are owned by institutional investors. Comparatively, 63.7% of VTEX shares are owned by institutional investors. 36.4% of Enfusion shares are owned by company insiders. Comparatively, 40.9% of VTEX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
VTEX beats Enfusion on 7 of the 13 factors compared between the two stocks.
About Enfusion
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.
About VTEX
VTEX provides software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce strategy, including building online stores, integrating, and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It has operations in Brazil, Argentina, Chile, Colombia, France, Italy, Mexico, Peru, Portugal, Romania, Singapore, Spain, the United Kingdom, and the United States. VTEX was founded in 2000 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.